Filing Analysis
Modular Medical, Inc. announced stock option awards to its Chairman, President, CFO, and Treasurer, Paul DiPerna, and its COO, Kevin Schmid, under the company's 2017 Equity Incentive Plan.
🚩 Red Flags
- Paul DiPerna holds multiple critical executive roles simultaneously, serving as Chairman, President, CFO, and Treasurer, which represents a high concentration of financial and administrative control.
📋 Key Facts
- On May 14, 2026, Paul DiPerna (Chairman, President, CFO, and Treasurer) was awarded 11,218 stock options.
- On May 14, 2026, Kevin Schmid (COO) was awarded 4,674 stock options.
- The stock options have an exercise price of $3.46 per share and expire on May 14, 2036.
- The options vest one-third on May 14, 2027, and 1/24th of the remaining shares monthly thereafter.
Modular Medical, Inc. entered into a placement agency agreement for a registered direct offering of 750,000 shares of common stock. The offering is expected to yield approximately $3.375 million in gross proceeds to the company.
🚩 Red Flags
- Shareholder dilution resulting from the issuance of 750,000 new shares.
- The relatively small size of the raise ($3.375M) may suggest immediate liquidity needs for a micro-cap company.
📋 Key Facts
- The offering involves 750,000 shares of common stock at a price resulting in $3.375 million gross proceeds.
- Maxim Group LLC is acting as the placement agent, receiving a 7% cash fee and up to $75,000 in expense reimbursement.
- Directors and executive officers are subject to a 90-day lock-up agreement.
- The company is prohibited from issuing additional securities for 45 days following the closing date of April 21, 2026.
- The offering was conducted under an existing Form S-3 registration statement (No. 333-287313).
Modular Medical, Inc. announced that it has regained compliance with Nasdaq's minimum bid price requirement as of April 15, 2026. The company received a formal notification from the Nasdaq Listing Qualifications Department confirming it met the standards of Rule 5550(a)(2).
🚩 Red Flags
- The company was previously non-compliant, indicating the stock had been trading below $1.00 for a sustained period
📋 Key Facts
- Notification of compliance received on April 15, 2026
- Compliance relates to Nasdaq Listing Rule 5550(a)(2) regarding the $1.00 minimum bid price
- The company issued a corresponding press release on April 16, 2026
- The matter is now considered closed by Nasdaq
Modular Medical, Inc. implemented a 1-for-30 reverse stock split of its common stock effective March 31, 2026. The split was previously approved by the board and shareholders to consolidate shares and likely maintain compliance with Nasdaq listing requirements.
🚩 Red Flags
- Large reverse split ratio (1-for-30) indicates significant share price erosion prior to the event.
- Authorized shares were not reduced in proportion to the split, which creates massive 'headroom' for future equity dilution without further shareholder votes.
📋 Key Facts
- Reverse stock split ratio of 1-for-30 effective as of 5:30 a.m. ET on March 31, 2026.
- The number of authorized shares of Common Stock and the par value ($0.001) remain unchanged.
- Common stock began trading on a post-split basis on March 31, 2026, under a new CUSIP (60785L306).
- No fractional shares will be issued; holders will receive cash in lieu of fractional shares.
- Outstanding equity awards and warrants will be adjusted (shares divided by 30, exercise price multiplied by 30).
Modular Medical, Inc. implemented a significant workforce reduction on March 12, 2026, laying off 20 employees to reduce cash burn. This reduction represents approximately 29% of the company's total workforce and is intended to prioritize projects with higher ROI.
🚩 Red Flags
- Substantial workforce reduction (29%) indicates significant liquidity or cash runway pressure.
- Explicit mention of the need to reduce 'cash burn' suggests the company may be facing a capital crunch.
- A reduction of this scale in a medical technology company may impact R&D timelines or commercialization efforts.
📋 Key Facts
- Layoff of 20 positions, representing 29% of the workforce, occurred on March 12, 2026.
- The reduction is expected to decrease annual operating expenses by approximately $3.4 million.
- Estimated non-recurring charges for severance are between $0.1 million and $0.2 million.
- The majority of restructuring charges are expected to be incurred by the quarter ending June 30, 2026.
- The stated purpose is to reduce operating expense and cash burn.
Modular Medical, Inc. closed a $12 million best-efforts public offering of common stock and warrants on March 4, 2026. The offering is highly dilutive, involving the issuance of approximately 68 million shares (including pre-funded warrants) and an equivalent number of common warrants at a combined price of $0.1762 per unit.
🚩 Red Flags
- Extreme dilution risk: The issuance of 68 million common warrants represents 100% warrant coverage relative to the shares/pre-funded warrants issued.
- Low nominal share price: The offering price of $0.1762 suggests the company is operating in penny stock territory, which often precedes volatility or potential delisting risks.
- Best-efforts offering: Unlike a firm commitment underwriting, a best-efforts deal may indicate lower institutional demand.
📋 Key Facts
- The company raised approximately $12 million in gross proceeds before fees and expenses.
- The offering consisted of 62,098,000 shares of common stock and 6,000,000 pre-funded warrants.
- Each share or pre-funded warrant was accompanied by a common warrant, totaling 68,098,000 common warrants with an exercise price of $0.1762.
- The combined public offering price was $0.1762 per share and accompanying warrant.
- Maxim Group LLC acted as the placement agent, receiving a 7% cash fee and $100,000 in expense reimbursements.
- Directors and executive officers are subject to a 90-day lock-up period.
Modular Medical, Inc. entered into a $350,000 secured revolving credit facility with its CEO, James E. Besser, on February 23, 2026. The facility is extremely short-term, maturing on March 25, 2026, and is secured by all of the company's assets and intellectual property.
🚩 Red Flags
- Related-party transaction involving the CEO as the primary lender.
- Extremely short-term maturity (30 days) suggests an immediate liquidity crisis.
- High cost of capital: 12% flat interest for a 30-day period is equivalent to an extremely high annual percentage rate.
- The Company has pledged its entire asset base and intellectual property for a relatively small $350,000 facility.
- The terms indicate the company is likely in desperate need of bridge financing to reach a larger equity raise.
📋 Key Facts
- The lender is James E. Besser, the Company's CEO.
- The credit facility provides up to $350,000 in revolving credit.
- The maturity date is March 25, 2026, approximately one month from the agreement date.
- Interest is set at a flat rate of 12% on each drawdown, regardless of the duration the funds are held.
- The loan is secured by all assets and intellectual property of the Company.
- Repayment is required earlier than maturity if the Company receives proceeds exceeding $2,000,000 from equity financings.
Modular Medical, Inc. held its 2026 annual meeting of shareholders where investors approved several major structural changes, including a significant increase in authorized shares and authorization for the Board to execute a reverse stock split.
🚩 Red Flags
- Approval of a reverse stock split (often used to maintain Nasdaq listing compliance or signal liquidity concerns).
- Significant increase in authorized shares (from 100M to 250M), which provides the company with massive potential dilution for future capital raises.
📋 Key Facts
- Shareholders approved an amendment to increase authorized common stock from 100,000,000 to 250,000,000 shares.
- Shareholders approved a proposal authorizing the Board of Directors to implement a reverse stock split at a ratio determined by the Board within a specified range.
- The reverse split can be effected at any time within one year from January 23, 2026, without further shareholder approval.
- All eight director candidates were elected to serve until the next annual meeting.
- Shareholders approved an increase of 3,000,000 shares for the 2017 Equity Incentive Plan.
- Farber Hass Hurley LLP was ratified as the independent registered public accounting firm for fiscal year ending March 31, 2026.
Modular Medical, Inc. has received a 180-day extension from Nasdaq to regain compliance with the $1 minimum bid price requirement. The company must achieve a closing bid price of at least $1.00 for 10 consecutive business days by June 29, 2026, or face delisting.
🚩 Red Flags
- Non-compliance with Nasdaq's $1 minimum bid price rule (Nasdaq Listing Rule 5550(a)(2)).
- Risk of delisting from the Nasdaq Capital Market if compliance is not met by June 29, 2026.
- The company has been under scrutiny for its share price since at least June 30, 2025.
📋 Key Facts
- Received written notification from Nasdaq on December 30, 2025, granting a 180-day extension to regain compliance with the Bid Price Rule.
- The deadline to meet the minimum bid price requirement is June 29, 2026.
- Compliance requires the stock to close at $1.00 or more for at least 10 consecutive business days.
- Failure to comply by the deadline will result in a delisting notice and potential appeal to a Nasdaq hearings panel.
Modular Medical, Inc. entered into a firm commitment underwriting agreement with Newbridge Securities Corporation for a public offering of common stock and warrants. The offering aims to raise approximately $4.68 million in gross proceeds through the sale of 12,173,000 shares and accompanying warrants.
🚩 Red Flags
- Significant dilution: Issuance of over 12 million new shares at a very low effective price ($0.38/share) will cause substantial dilution to existing shareholders.
- Warrant overhang: The issuance of millions of warrants (nearly 50% of the share count being offered) creates significant future dilution potential.
- Low share price: The effective price of $0.38 per share suggests the company is trading at a very low valuation, often characteristic of distressed micro-caps.
📋 Key Facts
- Offering size: 12,173,000 common shares (Firm Shares) and up to 6,086,500 warrants (Firm Warrants).
- Gross proceeds: Approximately $4.68 million.
- Pricing: Combined price of $0.77 per unit ($0.38/share and $0.01/warrant).
- Warrant terms: Exercise price of $0.45 per share, exercisable immediately, expiring in 5 years.
- Underwriter compensation: 7% cash fee plus reimbursement for expenses up to $85,000.
- Lock-up period: Directors and officers are subject to a 60-day lock-up; the Company is subject to a 90-day non-solicitation/transfer restriction.
- Underwriter Warrant: The underwriter receives a warrant for an aggregate of 852,110 shares (7% of Firm Shares).
Modular Medical, Inc. entered into inducement agreements to encourage holders of existing warrants to exercise them at a significant discount to market price. In exchange, the company will issue new warrants representing 50% of the exercised amount, resulting in immediate cash inflow but substantial future dilution.
🚩 Red Flags
- Significant anti-dilutive measures: Issuing new warrants to compensate for the discounted exercise of old ones creates massive potential share overhang.
- Desperation signaling: Inducement letters at a discount are typically used when a company is facing liquidity constraints and needs immediate cash.
- Fixed fee burden: The $400,000 fixed fee to Newbridge Securities must be paid regardless of the actual proceeds realized from warrant exercises.
📋 Key Facts
- Company entering into 'Inducement Letters' for both 2023 and 2025 warrant holders.
- Warrants to be exercised at a 'New Exercise Price' of $0.68 per share (a ~10% discount to the Sept 19, 2025, closing price of $0.7611).
- Expected gross proceeds from exercises: approximately $3.7 million.
- Company will issue 'New Warrants' for ~2,747,314 shares at an exercise price of $0.84 per share (a 10% premium to the Sept 19 closing price).
- The New Warrants have a term of 5 years and are expected to close around September 25, 2025.
- Newbridge Securities Corporation will receive a fixed fee of $400,000 plus expenses regardless of the final exercise amount.
Modular Medical, Inc. received a notice from Nasdaq stating the company is in violation of the minimum $1.00 bid price requirement. The company has been granted a 180-day compliance period ending December 29, 2025, to regain compliance.
🚩 Red Flags
- Delisting notice from Nasdaq
- Potential requirement for a reverse stock split to regain compliance
- Persistent low share price (below $1.00)
📋 Key Facts
- Received Nasdaq deficiency notice on June 30, 2025.
- Violation of Nasdaq Listing Rule 5550(a)(2) due to closing bid price below $1.00 for 30 consecutive business days ending June 27, 2025.
- Compliance period granted until December 29, 2025.
- To regain compliance, the stock must close at or above $1.00 for at least ten consecutive business days during the 180-day window.
- The company may be eligible for a second 180-day extension if it intends to cure the deficiency via a reverse stock split.
Modular Medical, Inc. announced the appointment of Jeffrey Goldberg to its Board of Directors, effective May 22, 2025. Mr. Goldberg brings extensive healthcare and technology board experience from roles at companies such as ATI Physical Therapy, Inc. and Lannett Company, Inc.
📋 Key Facts
- Jeffrey Goldberg appointed to the Board of Directors effective May 22, 2025.
- Mr. Goldberg has a background in healthcare/tech boards including ATI Physical Therapy, Eating Recovery Centers, Lannett Company, and Banza.
- Goldberg will participate in the Company’s Outside Director Compensation Plan.
- No family relationships or material related-party transactions (>$120,000) were disclosed regarding this appointment.
Modular Medical, Inc. completed a significant private placement of 6,247,656 units for approximately $12 million to fund working capital and product development. The offering includes warrants with an exercise price significantly below the current unit price, indicating potential future dilution.
🚩 Red Flags
- Significant potential dilution: Warrants are exercisable at $1.12, well below the $1.92 unit price.
- Warrant overhang: Placement agent and investors received substantial warrants that will likely convert to common stock.
- Lock-up/Restriction: Officers and directors are subject to a 60-day non-disposal period.
📋 Key Facts
- Closed Private Placement on March 26, 2025, raising ~$12 million gross proceeds.
- Units priced at $1.92 per Unit (consisting of 2 shares of Common Stock and 1 Warrant).
- Warrants have an exercise price of $1.12 per share.
- Placement Agent (Newbridge Securities Corporation) received a 7.25% cash fee plus warrants for 874,672 shares at $1.40/share.
- Company committed to filing a registration statement for resale within 30 days of closing.
- Proceeds intended for MODD1 product optimization and FDA submission for a tubeless version in Q3 2025.
Modular Medical, Inc. held its 2025 annual meeting of shareholders on February 28, 2025. Shareholders approved the election of seven directors, an increase in shares reserved for the Equity Incentive Plan, and the ratification of Farber Hass Hurley LLP as independent auditors.
📋 Key Facts
- Annual Meeting held on February 28, 2025, with a quorum representing ~74.9% of outstanding common stock.
- All seven director candidates (Duane DeSisto, Paul DiPerna, Steven Felsher, Morgan Frank, Philip Sheibley, Carmen Volkart, and Ellen O’Connor Vos) were elected.
- Proposal 2 was approved: Amendment to the 2017 Equity Incentive Plan to increase reserved shares by 3,000,000.
- Proposal 3 was approved: Ratification of Farber Hass Hurley LLP as independent registered public accounting firm for FY ending March 31, 2025.
Modular Medical, Inc. completed a firm commitment underwritten offering of 5,450,573 shares at $1.50 per share, raising approximately $8.2 million in gross proceeds. The offering included the issuance of warrants to the underwriter as compensation.
🚩 Red Flags
- Significant dilution: Issuance of over 5.4 million new shares at $1.50 per share.
- Warrant issuance: Underwriter received warrants representing 7% of the offering, which can lead to further dilution upon exercise.
- Potential liquidity need: The scale of the offering suggests a significant need for capital to fund operations.
📋 Key Facts
- Offering size: 5,450,573 shares of common stock.
- Public offering price: $1.50 per share.
- Gross proceeds: Approximately $8.2 million (before expenses).
- Underwriter: Titan Partners Group LLC (division of American Capital Partners, LLC).
- Warrants issued: 381,540 shares (7% of the offering) with an exercise price of $1.875.
- Lock-up period: 60 days for directors and executive officers following the closing date.
- Closing Date: November 25, 2024.
Modular Medical, Inc. announced that it has received U.S. FDA clearance for its MODD1 pump, allowing the company to market and sell the device in the United States.
📋 Key Facts
- FDA clearance received for the MODD1 pump on September 4, 2024.
- The clearance permits the commercialization of the MODD1 pump in the U.S. market.
Modular Medical, Inc. announced the cancellation of previously granted milestone-based options for executives after failing to meet an FDA clearance deadline by August 1, 2024. The Board has instead issued new option grants tied to a revised FDA notification deadline of December 31, 2024.
🚩 Red Flags
- Failure to meet a critical regulatory milestone (FDA clearance) by the previously established August 1, 2024 deadline.
- Heavy reliance on binary regulatory outcomes for executive compensation and employee retention/motivation.
- The company is operating under tight time constraints with a hard termination date of January 1, 2025, for new incentive grants.
📋 Key Facts
- Milestone 2 (FDA clearance notification) was due by August 1, 2024; this milestone was not met.
- Options previously granted for Milestone 2 were canceled on August 2, 2024.
- New options were granted to Paul DiPerna and Kevin Schmid on August 22, 2024, with an exercise price of $1.71 per share.
- The new executive options vest only if the Company receives FDA Notification by December 31, 2024; otherwise, they terminate on January 1, 2025.
- An additional 256,338 shares were authorized for non-executive employees under the same December 31, 2024 deadline.
Modular Medical, Inc. announced compensation adjustments and equity grants for its Chairman/President/CFO Paul DiPerna and COO Kevin Schmid, effective retroactively to April 1, 2024.
🚩 Red Flags
- Retroactive salary increases (effective April 1, reported April 8/10) can sometimes indicate management attempting to catch up on compensation or lack of timely administrative oversight.
- Increased executive compensation in a micro-cap environment without accompanying material revenue growth news is often viewed with skepticism by retail investors.
📋 Key Facts
- Paul DiPerna (Chairman, President, CFO, Treasurer) received a base salary increase from $300,000 to $360,000, retroactive to April 1, 2024.
- Paul DiPerna was granted an option to purchase 100,000 shares of common stock at an exercise price of $1.52 per share.
- Kevin Schmid (COO) received a base salary increase from $250,000 to $300,000, retroactive to April 1, 2024.
- Kevin Schmid was granted an option to purchase 50,000 shares of common stock at an exercise price of $1.52 per share.
- The options for both executives feature a 10-year term with monthly vesting after an initial one-year cliff.
Modular Medical, Inc. announced a firm commitment underwriting agreement to offer 9,090,910 shares of common stock at $1.10 per share. The offering aims to raise approximately $10 million in gross proceeds.
🚩 Red Flags
- Significant dilution: Issuance of over 9 million new shares at a low price point ($1.10) will result in substantial dilution for existing shareholders.
- Lock-up restrictions: The company is prohibited from issuing common stock or engaging in certain variable rate transactions for one year from closing.
📋 Key Facts
- Offering size: 9,090,910 shares of common stock plus a 30-day over-allotment option for up to 1,321,989 additional shares.
- Public offering price: $1.10 per share.
- Estimated gross proceeds: $10,000,000 (before expenses and commissions).
- Underwriter: Titan Partners Group LLC (a division of American Capital Partners, LLC).
- Expected closing date: February 21, 2024.
- Lock-up period: Directors and executive officers are prohibited from selling securities until May 21, 2024.
Modular Medical, Inc. reported the results of its annual meeting and announced a significant increase in authorized common stock from 50 million to 100 million shares. Additionally, the company has suspended its At-the-Market (ATM) equity offering program effective January 29, 2024.
🚩 Red Flags
- Suspension of ATM equity offering program suggests a pause in the company's ability or desire to raise capital through continuous offerings.
- Significant doubling of authorized share count (from 50M to 100M) often precedes potential dilutive financing events.
📋 Key Facts
- Authorized shares of common stock increased from 50,000,000 to 100,000,000 via Charter Amendment filed Feb 15, 2024.
- Shareholders approved an increase of 3,000,000 shares for the Amended 2017 Equity Incentive Plan.
- The company suspended sales under its At-the-Market (ATM) agreement with Leerink Partners LLC effective January 29, 2024.
- Annual meeting held Feb 13, 2024; quorum was 65.8% of voting power.
- Farber Hass Hurley LLP ratified as independent registered public accounting firm for FY ending March 31, 2024.
Modular Medical, Inc. announced the premarket submission of its MODD1 next-generation insulin pump to the FDA for 510(k) clearance on January 19, 2024.
📋 Key Facts
- Company submitted MODD1 next-generation insulin pump to the FDA for 510(k) clearance.
- The submission was made premarket as of January 19, 2024.
- The announcement was communicated via a press release (Exhibit 99.1).